Tag: retinal biologics industry

  • Comprehensive Retinal Biologics Market Analysis 2024: Size, Share, And Key Trends

    Comprehensive Retinal Biologics Market Analysis 2024: Size, Share, And Key Trends

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What is the Expected Growth Rate of the Retinal Biologics Market from 2024 to 2033?

    In recent times, the retinal biologics market has experienced significant expansion. Its size is forecasted to escalate from $22.48 billion in 2023 to $25.45 billion in 2024, reflecting a compound annual growth rate (CAGR) of 13.2%. The upsurge observed in previous periods can be accredited to factors including a rise in retinal disorder cases, aging demographic, heightened consciousness and early detection, advancing healthcare framework, and an increment in healthcare spending.

    The market size for retinal biologics is predicted to witness robust growth in the forthcoming years. The market is projected to surge to $39.69 billion in 2028 at a compound annual growth rate (CAGR) of 11.7%. This growth within the forecast period is credited to factors such as increased therapeutic applications, personalized treatments, growth in emerging markets, a robust biologics pipeline, inter-industry collaborations and partnerships, and government backing and initiatives. Some of the major trends expected during the forecast period encompass non-invasive delivery methods, the use of real-world evidence, widened indications, streamlined regulatory pathways, and a focus on patient-centric outcomes.

    Claim Your Free Sample of the Global Retinal Biologics Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=11911&type=smp

    What Key Factors Are Fueling the Growth of the retinal biologics Market?

    The retinal biologics market is projected to experience growth due to the rising incidence of diabetic eye disease. This condition, a complication of diabetes, can lead to vision loss or blindness in those affected by diabetes. With precise treatment and the possibility of early intervention, retinal biologics prove to be vital in preventing vision loss related to diabetic eye disease. For example, research by the American Medical Association in June 2023 showed that diabetic retinopathy impacted around 9.60 million people in the United States, making up 26.43% of the diabetic community. Also, vision-threatening diabetic retinopathy was found in about 1.84 million individuals, forming 5.06% of the diabetes patients. Hence, this growing incidence of diabetic eye disease is escalating the growth of the retinal biologics market.

    What Are the Major Segments of the Retinal Biologics Market?

    1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor

    2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications

    3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels

    What New Trends Are Transforming the Retinal Biologics Market?

    The advancing trend of product invention is playing a pivotal role in the progression of the retinal biologics market. To secure their spot and gain a competitive edge, principal businesses in this market are concentrating on introducing novel items. For example, in May 2023, the U.S. Food and Drug Administration approved the supplemental biologics license application (sBLA) of Vabysmo (faricimab) for retinal vein occlusion (RVO)-caused macular edema treatment proposed by F. Hoffmann-La Roche Ltd., a healthcare organization based in Switzerland. The approval was granted on the grounds of the results of two Phase III trials demonstrating early and consistent vision enhancement with Vabysmo, reaching the primary endpoint of parity with aflibercept. This medical solution is the first endorsed bispecific antibody dedicated to the treatment of neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Furthermore, research revealed that there were no signs of blood vessel leakage in the retina of Vabysmo users compared to those on aflibercept.

    Order Now for Fast Delivery of Your Retinal Biologics Market Report!

    https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

    Which Regions Are Driving Growth in the Retinal Biologics Market?

    North America was the largest region in the retinal biologics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    The Retinal Biologics Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the retinal biologics market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Retinal Biologics Market Include

    1. Retinal Biologics Market Executive Summary

    2. Retinal Biologics Market Segments

    3. Retinal Biologics Market Size And Template Market Growth Rate

    4. Key Retinal Biologics Market Trends

    5. Major Retinal Biologics Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Retinal Biologics Market

    26. Top Retinal Biologics Companies

    27. Retinal Biologics Market Opportunities And Strategies

    28. Retinal Biologics Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Retinal Biologics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

    Vitreoretinal Surgery Devices Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/vitreoretinal-surgery-devices-global-market-report

    Retinal Vein Occlusion Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Key Insights On The Retinal Biologics Market 2024 – Size, Driver, And Major Players

    Key Insights On The Retinal Biologics Market 2024 – Size, Driver, And Major Players

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    As per The Business Research Company’s Retinal Biologics Global Market Report 2024, the retinal biologics market is expected to show significant growth in the forecast period.

    The retinal biologics market has witnessed significant expansion in recent years, with promising projections for the future. Here’s a breakdown of the market’s journey:

    • Historical Growth: From $22.48 billion in 2023 to $25.45 billion in 2024, marking a CAGR of 13.2%. Factors driving this growth include increased incidence of retinal disorders, aging population, rising awareness, evolving healthcare infrastructure, and higher healthcare expenditure.
    • Forecasted Surge: Anticipated growth to $39.69 billion in 2028, boasting a CAGR of 11.7%. This growth trajectory is attributed to expanding therapeutic applications, personalized medicine, emerging market growth, a robust pipeline of biologics, collaborations, and government support.

    View More On The Retinal Biologics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

    Driving Forces Behind Market Expansion

    1. Diabetic Eye Disease Epidemic
    • The surge in diabetic eye disease cases is a major catalyst for market growth.
    • Retinal biologics offer precise and effective treatment options, aiding in early intervention and better outcomes.
    • In the U.S. alone, diabetic retinopathy affected 9.60 million individuals, with 1.84 million experiencing vision-threatening diabetic retinopathy.
    1. Product Innovation
    • Key players like Roche are spearheading innovation in the market.
    • Breakthrough products like Vabysmo (faricimab) for treating macular edema following retinal vein occlusion showcase significant advancements.
    • Vabysmo is the first bispecific antibody approved for the eye, offering promising results in various retinal conditions.
    1. Strategic Acquisitions
    • Coherus Biosciences’ acquisition of FYB203 from Klinge Biopharma strengthens its ophthalmology portfolio.
    • This move expands market opportunities and revenue potential, positioning Coherus as a significant player in the retinal biologics landscape.

    Market Segmentation and Regional Outlook
    The retinal biologics market is segmented based on drug class, indication, and distribution channel:

    1. Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor
    2. Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications
    3. Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Channels
    • Regional Dynamics: North America led the market in 2023, while the Asia-Pacific region is poised for the fastest growth in the forecast period.

    Conclusion: A Promising Future
    The retinal biologics market is experiencing unprecedented growth, fueled by technological advancements, strategic initiatives, and increasing healthcare needs. With innovative treatments on the horizon and a growing patient pool, the future looks bright for stakeholders in this dynamic sector. As the market continues to evolve, stakeholders must remain agile and collaborative to capitalize on emerging opportunities and drive positive outcomes for patients worldwide.

    Request A Sample Of The Global Retinal Biologics Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=11911&type=smp